FoRx Therapeutics

Executive Summary

FoRx Therapeutics is a privately held, clinical-stage biotechnology company based in Basel, Switzerland, pioneering next-generation precision therapeutics that target DNA replication stress in treatment-resistant cancers. Founded in 2018, the company is advancing a pipeline of first- and best-in-class small molecule inhibitors aimed at drugging key molecular targets involved in the replication stress response—a novel approach to cancer therapy. FoRx is currently in Phase 1 clinical development, leveraging its proprietary platform to address high unmet medical needs in aggressive, resistant tumor types. The company's strategy focuses on exploiting vulnerabilities in cancer cell DNA damage repair mechanisms, offering potential for improved efficacy and reduced toxicity compared to conventional treatments. With a strong scientific foundation and early-stage clinical assets, FoRx Therapeutics represents a compelling opportunity in the targeted oncology space, though it remains at an early stage with limited publicly available data.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 Initial Safety and Efficacy Data Readout for Lead Asset40% success
• Q4 2026IND Filing for Second-Generation Replication Stress Inhibitor70% success
• Q2 2026Presentation at Major Medical Conference (e.g., AACR or ASCO) on Preclinical/Clinical Updates80% success